Abstract
On 31 May, the Cystic Fibrosis (CF) Foundation of Bethesda, Maryland, announced that it will invest at least $30 million in a small biotech firm, Aurora Biosciences of San Diego, to identify compounds that might prove useful in treating CF. This project, fueled initially by a donation of $20 million from the Bill and Melinda Gates Foundation, marks a new departure in the growing trend of patient groups taking charge of biomedical research.

This publication has 0 references indexed in Scilit: